Loading...
Loading...
MLYS| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 60.1M |
| Operating I/L | -60.1M |
| Other Income/Expense | 3.8M |
| Interest Income | 3.8M |
| Pretax | -56.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -56.3M |
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapies for hypertension and associated cardiovascular diseases. Their primary product candidate, lorundrostat, is an orally administered aldosterone synthase inhibitor designed for patients with uncontrolled or resistant hypertension. The company generates revenue through the development and potential commercialization of lorundrostat, aiming to address the unmet medical needs in the treatment of hypertension and related cardiovascular conditions.
